IDO1’s Role in Cancer and the Immune System

IDO1, or indoleamine 2,3-dioxygenase 1, is an enzyme that breaks down the amino acid tryptophan and, in doing so, puts the brakes on immune cells that would otherwise attack threats like tumors. Cancers exploit this mechanism to shield themselves from the immune system, making IDO1 one of the most studied targets in cancer immunotherapy. Yet the biggest clinical trial of an IDO1-blocking drug ended in dramatic failure in 2018, forcing researchers to rethink how immune evasion actually works in tumors. The story of IDO1 is a window into why cancer immunology keeps humbling the people who study it.

What IDO1 Does at the Molecular Level

IDO1 catalyzes the first and rate-limiting step in the breakdown of the essential amino acid tryptophan along what is called the kynurenine pathway.¹ That means IDO1 chews up tryptophan and converts it into a molecule called kynurenine.² This matters because tryptophan is one of the amino acids that cells cannot make on their own. If you drain the local supply, cells that depend on it start to struggle. T cells, the immune system’s primary cancer-killing workforce, are especially sensitive to tryptophan depletion.

Normally, IDO1 expression in most cells is low. The enzyme gets turned on primarily by interferon-gamma, a signaling molecule that immune cells release during inflammation. Research in cervical cancer cell lines, for instance, showed that cells barely express IDO1 at all without interferon-gamma stimulation, but expression shoots up dramatically once the signal arrives.³ This creates a paradox: the very immune response that should fight a tumor also triggers a defense mechanism the tumor can hijack.

How IDO1 Shuts Down the Immune Response

The immunosuppressive effects of IDO1 work through at least three distinct mechanisms, and all of them feed off the same initial event: tryptophan gets consumed, kynurenine accumulates, and immune cells suffer on both counts.

First, as tryptophan levels drop, T cells activate a stress-response pathway through a molecule called GCN2 kinase. GCN2 senses the shortage of tryptophan by detecting the buildup of uncharged transfer RNA, essentially the molecular signal that says “we’re running out of building blocks.” When GCN2 flips on, T cells stop dividing and enter a state of deep unresponsiveness called anergy. Experiments showed that T cells engineered to lack GCN2 were resistant to IDO-mediated suppression entirely, confirming this pathway as a major enforcer.⁴

Second, the tryptophan shortage also suppresses another key growth-promoting pathway, mTOR, and triggers autophagy, a cellular recycling process that further constrains immune cell activity.⁵

Third, the kynurenine that accumulates on the other side of the reaction is not merely waste. Kynurenine activates a receptor called the aryl hydrocarbon receptor, and that activation drives the generation of regulatory T cells, a class of immune cells whose job is to dampen immune responses.⁶ So IDO1 doesn’t just starve the immune cells that attack tumors; it actively recruits immune cells that protect the tumor. It is a two-pronged assault on antitumor immunity.

Kynurenine Metabolites Do More Than Suppress T Cells

Kynurenine is only the first product in a cascade of downstream metabolites, and several of them have their own immunosuppressive or tumor-promoting effects. Kynurenine itself and downstream products like 3-hydroxykynurenine and kynurenic acid all activate the aryl hydrocarbon receptor, broadly suppressing antitumor immune cells.⁷ Another downstream metabolite, quinolinic acid, is a potent activator of a glutamate receptor called NMDA. In T cells and natural killer cells, this raises intracellular calcium and reactive oxygen species, suppressing their ability to produce interferon-gamma, one of the key signals needed to sustain an immune attack.⁷ In brain tumors specifically, quinolinic acid is also neurotoxic, and disruption of the kynurenine pathway has been linked to tumor progression through mechanisms beyond immune suppression alone.⁸

Beyond immune evasion, recent work shows that kynurenine pathway metabolites additionally promote tumor growth, metastatic spread, and resistance to chemotherapy through a mix of effects on both the tumor cells themselves and the surrounding immune environment.⁹ This means that even if you successfully block IDO1’s enzymatic activity, the downstream metabolites that have already accumulated may continue causing problems. And if any alternative pathway keeps producing them, the immunosuppressive environment persists.

IDO1 in the Tumor Microenvironment

Inside a tumor, IDO1 does not just affect T cells. Research has shown that tumor-expressed IDO1 orchestrates local and systemic immunosuppression by recruiting and activating myeloid-derived suppressor cells through a mechanism that depends on regulatory T cells. In human melanoma tumors, IDO1 expression was strongly associated with infiltration by these suppressor cells. When researchers treated tumor-bearing mice with a selective IDO1 inhibitor, it reversed the immunosuppressive environment by reducing the numbers of both suppressor cells and regulatory T cells while abolishing their suppressive function.¹⁰ This finding suggested a compelling drug target: block IDO1, and the tumor’s immune shield collapses. It was this kind of evidence that fueled intense enthusiasm for IDO1 inhibitors in the clinic.

The ECHO-301 Trial and Its Fallout

The most anticipated clinical test of IDO1 inhibition was the ECHO-301/KEYNOTE-252 trial, which randomized over 700 patients with advanced melanoma to receive either the IDO1 inhibitor epacadostat plus the checkpoint inhibitor pembrolizumab, or pembrolizumab alone. The trial was a comprehensive failure. Progression-free survival was virtually identical between the two groups, about 4.7 to 4.9 months, and overall survival showed no difference either.¹¹ The authors concluded that the usefulness of IDO1 inhibition as a strategy to enhance anti-PD-1 therapy in cancer remains uncertain.

The result sent shockwaves through the immuno-oncology field. Multiple other IDO1 inhibitor trials were scaled back or halted. The question shifted from “how quickly can we get IDO1 inhibitors to patients” to “why didn’t this work at all?”

Why Blocking IDO1 Alone May Not Be Enough

Several interlinked explanations have emerged for the failure, and they collectively paint a picture of a target that is real but far more embedded in a redundant biological network than anyone initially appreciated.

The most prominent explanation involves compensatory enzymes. When you block IDO1, the body has backup enzymes that can still break down tryptophan and produce kynurenine. These include TDO2 (tryptophan 2,3-dioxygenase, expressed mainly in the liver but also in some tumors), IDO2 (a less efficient relative of IDO1), and IL4I1 (an enzyme that generates immunosuppressive metabolites through a slightly different route). When IDO1 is knocked out in mice, TDO shows a compensatory increase.¹² Beyond enzyme redundancy, IDO1 blockade can be accompanied by metabolic diversion toward serotonin and melatonin pathways, gut microbiota-derived indole production, and metabolic rewiring within individual cell types.¹³ The tumor’s immunosuppressive environment is not a single switch but more like a web of overlapping circuits.

Another problem was the drug itself. Because tryptophan-analog inhibitors like epacadostat mimic an essential amino acid, they can interfere with other physiological processes unrelated to IDO1. These off-target effects include triggering cellular detoxification pathways known to affect inflammatory signaling, effectively muddying the therapeutic picture.¹⁴ The trial also did not select patients based on whether their tumors actually expressed IDO1 at high levels, raising the possibility that many participants never had the target in the first place.

The Kynurenine-to-Tryptophan Ratio as a Biomarker

One of the practical lessons from the ECHO-301 failure is that IDO1-directed therapy probably needs to be guided by biomarkers, not given to all comers. The ratio of kynurenine to tryptophan in a patient’s blood has been studied as a potential indicator of how active the IDO1 pathway is in a given person’s tumor.

In non-small cell lung cancer, a high kynurenine-to-tryptophan ratio correlated with older age, advanced tumor stage, and a specific tumor subtype (squamous cell carcinoma), while a low ratio correlated with lower IDO1 expression.¹⁵ In glioblastoma patients being considered for immunotherapy, those with a high kynurenine-to-tryptophan ratio had a mean overall survival of roughly 24 months, compared to about 39 months for those with lower values.¹⁶ A high ratio at the time of enrollment in an immunotherapy trial predicted worse outcomes, suggesting it could help clinicians identify which patients are most burdened by IDO1-driven immunosuppression and might benefit most from targeting it.

These findings remain preliminary. No blood-based biomarker for IDO1 activity has been validated in large prospective trials for routine clinical use, but the principle is clear: future IDO1-targeted therapies will likely need to select patients whose tumors actually depend on this pathway.

Combination Approaches and Triple Therapy

The failure of IDO1 inhibition as a single add-on to checkpoint immunotherapy has pushed the field toward more complex combination strategies. In preclinical work on colorectal cancer models, combining an IDO1 inhibitor with a PD-1 blocker increased the infiltration of cancer-killing CD8+ T cells and shifted the balance of immune cells in the tumor toward a more inflammatory state.¹⁷ Microsatellite-stable colorectal cancers are notoriously resistant to checkpoint immunotherapy on their own, so any approach that makes them more responsive attracts significant attention.

Even more striking results have come from triple-combination experiments. In a glioblastoma mouse model, combining IDO1 inhibition with radiation and PD-1 blockade more than doubled median survival compared to either radiation or immunotherapy alone.¹⁸ Long-term survival was observed only in the group receiving all three agents. The logic is straightforward: radiation damages the tumor and releases signals that attract immune cells, checkpoint blockade removes one set of brakes on those immune cells, and IDO1 inhibition removes another. None of the three alone was sufficient, but together they created a durable response. Whether this triple approach translates to humans remains to be tested in clinical trials.

Safety Concerns and the Autoimmunity Connection

Blocking IDO1 comes with a safety tradeoff that is worth understanding. Because IDO1 helps keep the immune system in check throughout the body, not just in tumors, inhibiting it can tip the balance toward autoimmune-like reactions. In a phase I trial of the IDO1 inhibitor LY3381916, the most prominent side effect in one patient subgroup was liver toxicity, affecting roughly a third of patients with triple-negative breast cancer. Dose-limiting toxicities included liver enzyme elevations and immune-related hepatitis, especially when the IDO1 inhibitor was combined with a PD-L1 blocker.¹⁹

The flip side of this coin is that IDO1’s immunosuppressive power could be harnessed to treat autoimmune diseases rather than cancer. In conditions like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease, where the immune system is overactive, boosting IDO1 expression could be therapeutic. Research has suggested that drugs capable of increasing IDO1 activity may represent valuable tools for several autoimmune conditions, and that such approaches could be more effective if tailored to the genetic profile of individual patients.²⁰ This means the same molecule is a villain in cancer and potentially a hero in autoimmunity, depending entirely on context.

IDO1 as a Signaling Molecule, Not Just an Enzyme

One of the more surprising discoveries about IDO1 is that its effects are not limited to its enzymatic activity. IDO1 also functions as an intracellular signal transducer: in response to the cytokine TGF-beta, it helps induce a stably regulatory phenotype in a type of immune cell called plasmacytoid dendritic cells.²¹ In plain terms, the protein itself, independent of whether it is breaking down tryptophan, can send signals that lock certain immune cells into an immunosuppressive state. Structural studies have identified specific regions of the IDO1 protein that undergo conformational changes when different molecules bind to it, suggesting these shape shifts are how the enzyme communicates with signaling partners.²²

This dual nature has serious implications for drug development. Most IDO1 inhibitors in clinical trials were designed to block the enzyme’s catalytic site, the part that breaks down tryptophan. But if the protein’s signaling function operates through a different part of the molecule, those drugs may only address half the problem. Future research has been urged to focus on non-enzymatic functions and downstream signaling networks of the IDO family as targets.²³

IDO1 Beyond Cancer and Autoimmunity

IDO1’s immunosuppressive role extends into pregnancy and gut health, which helps explain why the enzyme is so deeply conserved in evolution and why blocking it has systemic consequences.

The classic example is the maternal-fetal interface. In the late 1990s, a landmark experiment showed that pharmacologically inhibiting IDO in pregnant mice caused rejection of genetically foreign fetuses, suggesting that IDO1 in the placenta depleted tryptophan locally to keep the mother’s immune system from attacking the fetus. This became one of the most cited models in reproductive immunology. However, subsequent work complicated the picture considerably. The drug used in the original experiments, 1-methyltryptophan, was later found to also block placental tryptophan transport independently of IDO. And IDO-deficient mice carry pregnancies normally, with viable embryos surviving even when the fetus is genetically foreign to the mother.²⁴ IDO1 likely contributes to immune tolerance at the placenta, but it is not the single indispensable factor it was once thought to be.

In the gut, IDO1 interacts with the microbiome in a bidirectional relationship. Gut bacteria stimulate IDO1 activity; germ-free mice show substantially lower IDO1 activity than mice with normal microbial communities.²⁵ At the same time, when IDO1 is knocked out, gut bacteria shift toward species that use tryptophan to produce indolic compounds, which in turn strengthen gut barrier function by increasing tight junction proteins in intestinal cells.²⁶ IDO1 overexpression diminished these protective effects. This suggests that in the gut, IDO1 and the microbiome compete for tryptophan, and the balance between them affects intestinal health. It also hints at why IDO1 inhibitors can have gastrointestinal side effects.

The Evolutionary Depth of IDO1

IDO1 is not a recent evolutionary invention. Both IDO1 and its less efficient relative IDO2 are found across vertebrates, from fish and turtles to marsupials and monotremes like the platypus.²⁷ The gene duplication that gave rise to the two enzymes occurred before vertebrates diverged from one another, making these genes at least hundreds of millions of years old.²⁸

What changed over evolutionary time was efficiency. IDO2 enzymes in most species have low affinity for tryptophan, meaning they work sluggishly. IDO1 evolved a much higher affinity, and biochemical studies have traced this improvement to just two amino acid substitutions in the enzyme’s active site. When those two residues were swapped into IDO2, it gained IDO1-like efficiency.²⁹ Intriguingly, several lower vertebrate lineages lost IDO1 entirely while retaining the less efficient IDO2, suggesting that the powerful tryptophan-degrading capacity of IDO1 is not universally required for survival. In mammals, though, IDO1 appears to have been retained and refined, likely because the complex immune challenges of placental pregnancy, long-lived bodies susceptible to chronic infection, and dense microbial communities in the gut made potent tryptophan catabolism a useful tool for immune regulation. Those same features make IDO1 a particularly tempting target for tumors to exploit.